GLP-1 medicines such as semaglutide, the ingredient used in Ozempic and Wegovy, are increasingly becoming a major part of weight loss treatment for teens and young adults. According to a new study highlighted by Gizmodo, use of these drugs is climbing quickly in younger age groups as their popularity expands beyond adults.
The research suggests that this shift is changing how obesity treatment is approached for younger patients. As prescriptions for GLP-1 medications rise, bariatric surgery appears to be losing ground as a go-to option for weight loss in teens and young adults. That points to a broader change in clinical practice, with drug treatment playing a larger role than before.
Ozempic and related medications have already become some of the most talked-about drugs worldwide, largely because of their effects on weight and blood sugar. The new findings indicate that demand is now spreading more deeply into adolescent and young adult care, where families and doctors may be weighing less invasive options before considering surgery.
While the study points to fast growth in GLP-1 use among younger patients, the trend also raises bigger questions about long-term treatment, access, and how obesity care for teens will continue to evolve. For now, the data suggests these medications are quietly becoming one of the leading weight loss tools for this age group.
